Loading market dashboard
Atai Beckley Inc.
ATAIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Nike Inc (NYSE:NKE, XETRA:NKE) is leaning on its football division to sustain the brand's ongoing turnaround, positioning the category as the next major...
A stronger-than-expected US labor market report for May calmed fears of an economic slowdown but unsettled financial markets, with Treasury yields surging,...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has kept Jefferies analysts bullish on the company following a fireside chat in New York City, with the firm reiterating a 'Buy' rating and a $10 price target on the company, implying roughly 120% upside from current levels. The firm's outlook centers on strengthening late-stage visibility across the company's psychedelic pipeline and what it described as an increasingly constructive regulatory backdrop.
MYR Group Inc. (NASDAQ:MYRG) has agreed to acquire all outstanding capital stock of Valley Holdings Inc and its subsidiaries, including Valley Electric...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the launch of a new Patient Impact Grant Program aimed at supporting non-profit organizations working to improve mental health outcomes through community initiatives, education and research. The clinical-stage biotechnology company said the program will award three grants of $20,000 each to mission-driven organizations focused on advancing mental health support and patient outcomes.
Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research. Grant Funding Areas Community Support: Organizations who support equitable access to existing and emerging mental health treatments.
11:55am: Balancing act Gina Bolvin, President of Bolvin Wealth Management Group, said today’s economic data underscores a “tougher balancing act” for...
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company's management team will participate in multiple upcoming investor conferences in June 2026.
8.24am: HSBC, BP among morning's ex-div stocks The FTSE 100 is also facing a near 20-point drag from stocks trading ex-dividend this morning, led by HSBC,...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple Phase III and Phase II readouts expected over the next several years that could help define the outlook for its $1B+ portfolio, according to Jefferies analysts. Following the company's Q1 results and corporate update, the firm highlighted multiple programs targeting treatment-resistant depression (TRD) and related psychiatric conditions, including BPL-003, VLS-01, and EMP-01, as key drivers of upcoming clinical and data readouts.
Tesla Inc (NASDAQ:TSLA) had its price target raised modestly by UBS to $364 from $352, as the bank said the electric vehicle maker’s first-quarter update...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treatment-resistant depression therapy in the second quarter of 2026, while projecting its cash reserves will support operations into 2029 as the company advances multiple mental health treatment candidates through clinical development. In a statement released alongside the company's first quarter earnings on Tuesday, AtaiBeckley said its Phase 3 ReConnection program for BPL-003, a mebufotenin benzoate nasal spray being developed for treatment-resistant depression (TRD), remains on track to begin in Q2 2026 following an End-of-Phase 2 meeting with the US Food and Drug Administration.
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029 NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline. First Quarter 2026 Highlights BPL-003 (TRD): Phase 3 pivotal ReConnection program on track to initiate in Q2 2026.
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Microsoft Corp (NASDAQ:MSFT) shares have slid roughly 12% since its fiscal second-quarter results, and heading into Wednesday's fiscal third-quarter report,...
The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile domestic political news stories, but the implications for this small but growing industry are tremendous. Indeed, within days, the FDA began to make moves, awarding national priority vouchers to select companies developing drugs in this category, thereby reducing drug review times considerably.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in OVID Health's 2026 Patient Participant Index (PPI), in collaboration with the Psychedelic Participant Advocacy Network (PsyPAN), in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research. The recognition highlights AtaiBeckley's multiyear collaboration with PsyPAN to integrate the lived experiences of clinical trial participants into the responsible development of novel mental health therapies and amplify these learnings across the sector.
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced expanded Phase 2a results for EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder (SAD) (n=70), demonstrating clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges' g=0.84) on the patient-reported Social Phobia Inventory (SPIN), a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination (SAFE), and a previously reported −11.9-point LS mean difference (LSMD) on the Liebowitz Social Anxiety Scale (LSAS) versus placebo (g=0.45), with 49% responder rates on both Clinical Global Impression-Improvement (CGI-I) (previously reported) and Patient Global Impressions of Change (PGI-C). EMP-01 was well tolerated, with no severe or serious adverse events.
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
Promising therapies for mental illnesses could see their regulatory reviews quickened. AtaiBeckley is a potential leader in psychedelic treatments.
While many investors focused on the annual 4/20 holiday, expecting the usual buzz around marijuana stocks, a quiet revolution was unfolding in Washington. Over a weekend when most of the market was logged off, the administration issued a bombshell executive order designed to fast-track psychedelic medicines to market.
AtaiBeckley (NASDAQ: ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.
ATAI surged 28.1% in premarket trading as investors piled into the sector after the administration's weekend directive. The move sparked a broad wave of buying across psychedelic‑focused companies.
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status, but reinforces a federal move toward medical, evidence-based framework for other alternative medicines, like cannabis, experts say.
The FDA will fast-track certain psychedelic treatments. Several biotech stocks are soaring due to the new policy.
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and expanding patient access for certain serious mental health conditions, including post-traumatic stress disorder (PTSD) and treatment-resistant depression. The executive order, signed by Trump on Saturday, directs the US Food and Drug Administration (FDA) Commissioner to prioritize review pathways for psychedelic drugs that have received Breakthrough Therapy designation for serious mental illnesses and meet criteria under a national voucher program designed to speed regulatory review.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Silverbullet Data Services Group PLC (LSE:SBDS) saw its shares rise 10.5%, to 21p, after revealing its first period of positive EBITDA, in the first quarter...
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to implications for companies such as AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) and peers developing next-generation mental health treatments. Spravato (esketamine nasal spray), which is approved for treatment-resistant depression (TRD), generated $468 million in global sales in the first quarter of 2026, representing a 46% increase year over year.
Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales...
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27)
Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF) fell 7% to 320p on Thursday after Peel Hunt downgraded the fuel cell technology developer to 'sell' from...
AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029.
The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effects lasting up to 12 weeks. The Phase 2a study found that 66.7% of participants achieved a clinically significant reduction in symptoms by Day 2.
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy Designation, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (≥50% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5/6) of participants in the 10 mg cohort and 66.7% (4/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose. Phase 3 studies are on track to initiate in Q2 2026 following recent FDA End-of-Phase 2 (EOP2) alignment.
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current levels. In a note to clients, analysts highlighted the company's position in the emerging field of psychedelic medicine for mental health.
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to increase its visibility among institutional investors and trigger buying from passive investment funds. The clinical-stage biotechnology company announced that it joined the S&P Total Market Index, the S&P Completion Index and CRSP US benchmark indices, effective March 23, 2026.
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500® Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting AtaiBeckley's enhanced eligibility following its U.S. re-domiciliation and building on its addition to the Nasdaq Biotechnology Index in December 2025 NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to...
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Designation. We also know BPL-003 is expected to enter Phase 3 in Q2 2026. VLS-01 and EMP-01 add pipeline depth.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study of its investigational treatment for treatment-resistant depression (TRD), BPL-003, reporting rapid and sustained antidepressant effects in a small patient cohort. The data, published in the Journal of Psychopharmacology, comes from Cohort 1 of the four-part trial.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression while continuing development of additional mental health therapies. The clinical-stage biotechnology company said it remains on track to initiate two parallel Phase 3 pivotal studies of BPL-003, a mebufotenin benzoate nasal spray, in the second quarter of 2026 following a successful End-of-Phase 2 meeting with the US Food and Drug Administration.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today highlighted key clinical, regulatory, and operational milestones from its 2026 Virtual Investor Day, including the advancement of BPL‑003 (mebufotenin benzoate nasal spray) toward Phase 3 initiation in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.
